Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Butantan-DV
Synonyms :
BDV
Class :
Immunizations and Vaccines
Dosage forms & Strengths
FDA approval is still pending
It is indicated for Immunization against Dengue
This vaccine is designed to fight all four types of the dengue virus (DENV)
It uses a live, weakened, four-part approach to boost its effectiveness and ability to stimulate an immune response
The immune system is trained by the vaccine to identify and combat DENV
It accomplishes this by displaying DENV-1, -3, and -4 components in addition to a DENV-2/-4 mix
Dose Adjustments
Limited data is available
Dosage Forms & Strengths
This is used as an investigational drug and for research purpose which is pending for FDA approval
It is indicated for Immunization against Dengue
This vaccine is designed to fight all four types of the dengue virus (DENV)
It uses a live, weakened, four-part approach to boost its effectiveness and ability to stimulate an immune response
The immune system is trained by the vaccine to identify and combat DENV
It accomplishes this by displaying DENV-1, -3, and -4 components in addition to a DENV-2/-4 mix
Safety and efficacy are not seen in pediatrics < 2 years
Dose Adjustments
Limited data is available
Refer to the adult dosing
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
Actions and Spectrum
Phase 2 results shown that the human body multiplies the four attenuated virus serotypes and produces a balanced antibody response.
Limited data is available
Limited data is available
Contraindication/Caution:
Contraindications
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology
After just one vaccination, it is produced neutralizing antibodies against each of the four DENV serotypes, and 75% of the subjects experienced a tetravalent neutralizing humoral response.
Pharmacodynamics
Limited information is present
Pharmacokinetics
ADME is not available
Administration
Under clinical trials regarding the route
Patient information leaflet
Generic Name: butantan–dengue vaccine
Pronounced: boo-tuhn-tahn-den-gee văk-seen
Why do we use butantan–dengue vaccine?
It is an experimental, single-dose, live, attenuated tetravalent vaccination , although further information on its overall effectiveness is needed.